One in two of us will be diagnosed with cancer at some point in our lifetimes.
Head and neck cancer is now the most common cancer in India. A cancer affecting the senses more than any other, even those head and neck cancer patients who survive their cancer can be left with lifelong side-effects, no longer able to eat, taste or speak normally.
Head and neck cancer is a particularly urgent cause in Asia and it is for this reason that the Asian Business Publications group is pleased to be able to support Oracle Cancer Trust this year.
Oracle Cancer Trust is the UK’s leading charity dedicated to funding head and neck cancer research.www.oraclecancertrust.org)
Just one example of work being funded by Oracle is the pioneering thyroid cancer research being undertaken by Dr Malin Pedersen at London’s Institute of Cancer Research - Under the guidance of Dr Pedersen, her team is testing new drugs which can awaken the patient’s immune system to fight thyroid cancer. Like all other cancers, thyroid cancer is a disease that affects the genetic code of cells. These genetic changes can allow tumours to grow more efficiently, spread and become resistant to treatment. In their project, Dr Pedersen and her team are testing new drug combinations for patients with treatment-resistant thyroid cancer who do not respond to conventional therapies.
One of the new approaches being tested will involve using drugs that can awaken the patient’s own immune system to the presence of the tumour. These so-called immunotherapies are showing huge promise across a wide variety of tumour types. Oracle Honorary Trustee Professor Kevin Harrington recently led the UK arm of an international clinical trial showing the effectiveness of an immunotherapy called nivolumab in improving survival for patients with other advanced head and neck cancers.
Find out more about Oracle’s groundbreaking research at www.oraclecancertrust.org/research
[email protected] - www.oraclecancertrust.org
020 7922 7924
